| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 32 | 2024 | 390 | 8.090 |
Why?
|
| Multiple Sclerosis | 14 | 2025 | 386 | 8.030 |
Why?
|
| Dementia | 24 | 2021 | 489 | 6.650 |
Why?
|
| Cholinergic Antagonists | 14 | 2024 | 53 | 6.440 |
Why?
|
| Nursing Homes | 24 | 2021 | 107 | 6.290 |
Why?
|
| Urinary Bladder, Overactive | 8 | 2021 | 32 | 5.180 |
Why?
|
| Cholinesterase Inhibitors | 8 | 2024 | 103 | 4.280 |
Why?
|
| Medicare | 24 | 2025 | 468 | 3.710 |
Why?
|
| Depression | 16 | 2020 | 1362 | 3.430 |
Why?
|
| United States | 102 | 2025 | 11711 | 3.320 |
Why?
|
| Muscarinic Antagonists | 8 | 2024 | 38 | 2.900 |
Why?
|
| Practice Patterns, Physicians' | 20 | 2024 | 772 | 2.870 |
Why?
|
| Aged | 99 | 2025 | 21446 | 2.850 |
Why?
|
| Drug Utilization | 15 | 2017 | 169 | 2.750 |
Why?
|
| Drug Prescriptions | 18 | 2023 | 244 | 2.700 |
Why?
|
| Psychotropic Drugs | 15 | 2019 | 130 | 2.670 |
Why?
|
| Psychotic Disorders | 10 | 2013 | 149 | 2.530 |
Why?
|
| Homes for the Aged | 8 | 2017 | 26 | 2.510 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 882 | 2.490 |
Why?
|
| Pneumonia | 5 | 2022 | 341 | 2.280 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 7 | 2017 | 238 | 2.210 |
Why?
|
| Retrospective Studies | 70 | 2025 | 17520 | 2.180 |
Why?
|
| Analgesics, Opioid | 11 | 2025 | 468 | 2.130 |
Why?
|
| Ambulatory Care | 12 | 2021 | 415 | 2.080 |
Why?
|
| Paroxetine | 4 | 2017 | 29 | 2.030 |
Why?
|
| Aged, 80 and over | 49 | 2025 | 7137 | 2.010 |
Why?
|
| Health Expenditures | 6 | 2024 | 117 | 1.960 |
Why?
|
| Fingolimod Hydrochloride | 4 | 2024 | 37 | 1.940 |
Why?
|
| Immunosuppressive Agents | 6 | 2025 | 678 | 1.940 |
Why?
|
| Logistic Models | 26 | 2024 | 1862 | 1.870 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2023 | 295 | 1.860 |
Why?
|
| Humans | 167 | 2025 | 133147 | 1.810 |
Why?
|
| Central Nervous System Stimulants | 5 | 2017 | 131 | 1.790 |
Why?
|
| Male | 109 | 2025 | 65472 | 1.770 |
Why?
|
| Female | 113 | 2025 | 71382 | 1.740 |
Why?
|
| Prescription Drugs | 4 | 2023 | 59 | 1.720 |
Why?
|
| Polypharmacy | 7 | 2022 | 40 | 1.670 |
Why?
|
| Antidepressive Agents | 8 | 2025 | 327 | 1.650 |
Why?
|
| Patient Readmission | 3 | 2022 | 427 | 1.530 |
Why?
|
| Cohort Studies | 28 | 2022 | 5188 | 1.530 |
Why?
|
| Health Care Surveys | 14 | 2021 | 295 | 1.520 |
Why?
|
| Recurrence | 3 | 2025 | 1469 | 1.520 |
Why?
|
| Accidental Falls | 5 | 2024 | 120 | 1.510 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 124 | 1.450 |
Why?
|
| Cross-Sectional Studies | 28 | 2024 | 3734 | 1.440 |
Why?
|
| Glatiramer Acetate | 3 | 2025 | 15 | 1.400 |
Why?
|
| Fractures, Bone | 4 | 2016 | 211 | 1.380 |
Why?
|
| Parkinson Disease | 4 | 2020 | 740 | 1.350 |
Why?
|
| Machine Learning | 3 | 2023 | 345 | 1.330 |
Why?
|
| Office Visits | 6 | 2020 | 78 | 1.320 |
Why?
|
| Cognitive Dysfunction | 3 | 2020 | 316 | 1.320 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2022 | 288 | 1.310 |
Why?
|
| Adolescent | 47 | 2025 | 20528 | 1.270 |
Why?
|
| Dimethyl Fumarate | 3 | 2024 | 11 | 1.270 |
Why?
|
| Medication Adherence | 5 | 2025 | 340 | 1.240 |
Why?
|
| Medicaid | 14 | 2023 | 252 | 1.200 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2021 | 38 | 1.150 |
Why?
|
| Crotonates | 2 | 2024 | 7 | 1.080 |
Why?
|
| Adult | 36 | 2025 | 31608 | 1.070 |
Why?
|
| Middle Aged | 38 | 2025 | 28911 | 1.060 |
Why?
|
| Quality of Life | 8 | 2022 | 2160 | 1.030 |
Why?
|
| Activities of Daily Living | 6 | 2022 | 430 | 1.020 |
Why?
|
| Hip Fractures | 2 | 2018 | 74 | 1.000 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 1163 | 0.990 |
Why?
|
| Medication Errors | 4 | 2015 | 207 | 0.960 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2025 | 13 | 0.960 |
Why?
|
| Young Adult | 18 | 2025 | 9917 | 0.950 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 27 | 0.950 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 42 | 0.930 |
Why?
|
| Heart Failure | 10 | 2023 | 2428 | 0.910 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 1467 | 0.890 |
Why?
|
| Toluidines | 1 | 2024 | 4 | 0.880 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 45 | 0.870 |
Why?
|
| Risk | 12 | 2018 | 781 | 0.870 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 138 | 0.860 |
Why?
|
| Delirium | 1 | 2024 | 62 | 0.840 |
Why?
|
| Depressive Disorder, Major | 3 | 2025 | 472 | 0.840 |
Why?
|
| Mental Disorders | 8 | 2024 | 893 | 0.820 |
Why?
|
| Nitriles | 1 | 2024 | 155 | 0.820 |
Why?
|
| Longitudinal Studies | 10 | 2024 | 1514 | 0.810 |
Why?
|
| Multivariate Analysis | 13 | 2016 | 1463 | 0.790 |
Why?
|
| Case-Control Studies | 11 | 2024 | 3406 | 0.790 |
Why?
|
| Prevalence | 11 | 2025 | 2628 | 0.790 |
Why?
|
| Hospitalization | 12 | 2024 | 1910 | 0.780 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 2092 | 0.750 |
Why?
|
| Propensity Score | 9 | 2017 | 263 | 0.730 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 3 | 0.720 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 168 | 0.720 |
Why?
|
| Biological Products | 1 | 2023 | 139 | 0.710 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 55 | 0.710 |
Why?
|
| Asthma | 2 | 2019 | 807 | 0.700 |
Why?
|
| Cognition | 3 | 2023 | 815 | 0.700 |
Why?
|
| Withholding Treatment | 2 | 2020 | 69 | 0.690 |
Why?
|
| Mandelic Acids | 1 | 2020 | 6 | 0.680 |
Why?
|
| Urological Agents | 1 | 2020 | 5 | 0.680 |
Why?
|
| Drug Therapy | 4 | 2008 | 92 | 0.670 |
Why?
|
| Pyrrolidines | 1 | 2020 | 42 | 0.670 |
Why?
|
| Benzofurans | 1 | 2020 | 24 | 0.670 |
Why?
|
| Comorbidity | 7 | 2020 | 1620 | 0.670 |
Why?
|
| Drug Utilization Review | 3 | 2015 | 33 | 0.640 |
Why?
|
| Risk Factors | 17 | 2024 | 10930 | 0.630 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2021 | 227 | 0.630 |
Why?
|
| Outpatients | 7 | 2023 | 275 | 0.610 |
Why?
|
| Prescriptions | 4 | 2024 | 42 | 0.610 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 242 | 0.610 |
Why?
|
| Immunologic Factors | 3 | 2024 | 186 | 0.600 |
Why?
|
| Residence Characteristics | 6 | 2019 | 290 | 0.580 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 225 | 0.580 |
Why?
|
| Cost of Illness | 1 | 2020 | 277 | 0.570 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 76 | 0.560 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 30 | 0.560 |
Why?
|
| Documentation | 1 | 2019 | 122 | 0.550 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 562 | 0.540 |
Why?
|
| Melanoma | 1 | 2024 | 953 | 0.540 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 123 | 0.540 |
Why?
|
| Age Factors | 10 | 2024 | 2954 | 0.530 |
Why?
|
| Data Collection | 4 | 2013 | 395 | 0.530 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 893 | 0.530 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 491 | 0.530 |
Why?
|
| Bipolar Disorder | 6 | 2019 | 367 | 0.530 |
Why?
|
| Child | 35 | 2024 | 25828 | 0.530 |
Why?
|
| Patient Discharge | 2 | 2022 | 520 | 0.530 |
Why?
|
| Incidence | 10 | 2019 | 3385 | 0.520 |
Why?
|
| Proton Pump Inhibitors | 2 | 2019 | 275 | 0.520 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 9 | 0.520 |
Why?
|
| Odds Ratio | 6 | 2021 | 1253 | 0.510 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 27 | 0.510 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 908 | 0.510 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 341 | 0.500 |
Why?
|
| Linear Models | 5 | 2023 | 719 | 0.500 |
Why?
|
| Health Status | 2 | 2015 | 414 | 0.490 |
Why?
|
| Risk Adjustment | 1 | 2015 | 60 | 0.450 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 247 | 0.420 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 3087 | 0.410 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 318 | 0.410 |
Why?
|
| Mortality | 1 | 2015 | 260 | 0.400 |
Why?
|
| Treatment Outcome | 11 | 2023 | 13093 | 0.400 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2017 | 29 | 0.400 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 138 | 0.390 |
Why?
|
| Neurodegenerative Diseases | 1 | 2015 | 284 | 0.380 |
Why?
|
| Galantamine | 2 | 2022 | 11 | 0.380 |
Why?
|
| Rivastigmine | 2 | 2022 | 18 | 0.380 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 493 | 0.380 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 16 | 0.370 |
Why?
|
| Osteoarthritis | 1 | 2013 | 103 | 0.370 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 40 | 0.370 |
Why?
|
| Depressive Disorder | 1 | 2015 | 485 | 0.360 |
Why?
|
| Joint Diseases | 1 | 2011 | 34 | 0.360 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 483 | 0.360 |
Why?
|
| Indans | 2 | 2022 | 56 | 0.360 |
Why?
|
| Acetylcholinesterase | 2 | 2021 | 26 | 0.350 |
Why?
|
| Home Care Services | 1 | 2012 | 81 | 0.350 |
Why?
|
| Methotrexate | 2 | 2023 | 355 | 0.350 |
Why?
|
| Emergency Service, Hospital | 6 | 2024 | 1166 | 0.350 |
Why?
|
| Cerebrovascular Disorders | 2 | 2010 | 124 | 0.340 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 679 | 0.340 |
Why?
|
| Neoplasms | 2 | 2023 | 2984 | 0.340 |
Why?
|
| Steroids | 1 | 2011 | 211 | 0.340 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 106 | 0.330 |
Why?
|
| Sex Factors | 4 | 2024 | 1350 | 0.330 |
Why?
|
| Geography | 3 | 2019 | 124 | 0.330 |
Why?
|
| Administration, Oral | 2 | 2024 | 718 | 0.330 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 658 | 0.330 |
Why?
|
| Risk Assessment | 5 | 2024 | 3715 | 0.330 |
Why?
|
| Off-Label Use | 1 | 2010 | 28 | 0.320 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2017 | 77 | 0.320 |
Why?
|
| Piperidines | 2 | 2022 | 241 | 0.320 |
Why?
|
| Drug Interactions | 3 | 2019 | 259 | 0.310 |
Why?
|
| Health Care Costs | 2 | 2024 | 409 | 0.310 |
Why?
|
| Child Welfare | 1 | 2009 | 67 | 0.310 |
Why?
|
| Drug Labeling | 1 | 2009 | 30 | 0.310 |
Why?
|
| Pediatrics | 1 | 2019 | 1219 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 314 | 0.300 |
Why?
|
| Needs Assessment | 1 | 2009 | 180 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 57 | 0.290 |
Why?
|
| Propylamines | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hypertension | 3 | 2016 | 1402 | 0.270 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 397 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 221 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1714 | 0.260 |
Why?
|
| Time Factors | 6 | 2017 | 6541 | 0.260 |
Why?
|
| Health Services Needs and Demand | 4 | 2015 | 177 | 0.240 |
Why?
|
| Benzodiazepines | 4 | 2012 | 111 | 0.240 |
Why?
|
| SEER Program | 2 | 2024 | 222 | 0.240 |
Why?
|
| Fluoxetine | 1 | 2025 | 46 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 904 | 0.230 |
Why?
|
| Health Surveys | 3 | 2012 | 259 | 0.230 |
Why?
|
| Algorithms | 2 | 2023 | 1730 | 0.230 |
Why?
|
| Chronic Pain | 2 | 2024 | 149 | 0.230 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3985 | 0.220 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 936 | 0.210 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 78 | 0.210 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 42 | 0.210 |
Why?
|
| Naloxone | 1 | 2024 | 50 | 0.210 |
Why?
|
| Pain | 3 | 2024 | 469 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2016 | 1240 | 0.210 |
Why?
|
| Acute Pain | 1 | 2023 | 17 | 0.210 |
Why?
|
| Fees, Pharmaceutical | 1 | 2003 | 1 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 313 | 0.200 |
Why?
|
| Atomoxetine Hydrochloride | 2 | 2017 | 15 | 0.200 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2022 | 8 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 81 | 0.200 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2022 | 25 | 0.200 |
Why?
|
| Frailty | 1 | 2025 | 134 | 0.200 |
Why?
|
| Medicare Part D | 2 | 2015 | 17 | 0.200 |
Why?
|
| Cannabidiol | 1 | 2022 | 22 | 0.190 |
Why?
|
| Geriatrics | 1 | 2003 | 73 | 0.190 |
Why?
|
| Anxiety | 4 | 2011 | 1005 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 230 | 0.190 |
Why?
|
| Child Psychiatry | 2 | 2024 | 16 | 0.190 |
Why?
|
| Pharmacists | 3 | 2000 | 105 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 5434 | 0.190 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 276 | 0.190 |
Why?
|
| Managed Care Programs | 2 | 2019 | 61 | 0.180 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.180 |
Why?
|
| Diltiazem | 1 | 2021 | 14 | 0.180 |
Why?
|
| Sitagliptin Phosphate | 1 | 2021 | 8 | 0.180 |
Why?
|
| Aftercare | 1 | 2022 | 156 | 0.180 |
Why?
|
| Citalopram | 1 | 2021 | 30 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2005 | 572 | 0.180 |
Why?
|
| Sotalol | 1 | 2021 | 34 | 0.180 |
Why?
|
| Body Mass Index | 4 | 2023 | 1710 | 0.170 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 30 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 116 | 0.170 |
Why?
|
| Models, Economic | 2 | 2020 | 55 | 0.170 |
Why?
|
| Professional Autonomy | 1 | 2001 | 31 | 0.170 |
Why?
|
| Injections | 1 | 2021 | 156 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2024 | 660 | 0.170 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 86 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 335 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2023 | 399 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2021 | 328 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 166 | 0.170 |
Why?
|
| Quetiapine Fumarate | 2 | 2012 | 17 | 0.170 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 15 | 0.170 |
Why?
|
| Nurse Practitioners | 1 | 2001 | 51 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2020 | 1236 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 376 | 0.160 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 26 | 0.160 |
Why?
|
| Risperidone | 2 | 2012 | 60 | 0.160 |
Why?
|
| Physician Assistants | 1 | 2001 | 78 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 441 | 0.160 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2022 | 225 | 0.160 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1996 | 54 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 191 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2015 | 808 | 0.150 |
Why?
|
| Weight Gain | 2 | 2019 | 412 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 1999 | 28 | 0.150 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 158 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1418 | 0.150 |
Why?
|
| Drug Monitoring | 3 | 2024 | 185 | 0.150 |
Why?
|
| Vomiting | 1 | 1999 | 110 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2019 | 423 | 0.150 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 60 | 0.150 |
Why?
|
| Medical Errors | 1 | 2000 | 160 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 185 | 0.140 |
Why?
|
| Sinusitis | 1 | 2019 | 114 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 234 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 248 | 0.130 |
Why?
|
| Societies, Pharmaceutical | 1 | 1996 | 16 | 0.130 |
Why?
|
| Amitriptyline | 3 | 2002 | 26 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2023 | 14862 | 0.120 |
Why?
|
| Prognosis | 2 | 2023 | 5030 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2024 | 429 | 0.120 |
Why?
|
| Research Design | 1 | 2020 | 757 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 99 | 0.120 |
Why?
|
| Models, Statistical | 2 | 2015 | 499 | 0.120 |
Why?
|
| Medicare Part C | 1 | 2016 | 39 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 316 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 270 | 0.120 |
Why?
|
| Causality | 1 | 2015 | 94 | 0.120 |
Why?
|
| Behavior | 1 | 2015 | 75 | 0.110 |
Why?
|
| Electronic Health Records | 2 | 2020 | 804 | 0.110 |
Why?
|
| Blood Glucose | 3 | 2023 | 1184 | 0.110 |
Why?
|
| Mental Health Services | 1 | 2018 | 279 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2018 | 251 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 335 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2015 | 195 | 0.110 |
Why?
|
| Epilepsy | 1 | 2022 | 898 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2241 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2015 | 128 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1558 | 0.110 |
Why?
|
| Pharmaceutical Services | 2 | 2019 | 38 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 612 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2018 | 386 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 294 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 192 | 0.100 |
Why?
|
| Analgesics | 2 | 2024 | 131 | 0.100 |
Why?
|
| Infant | 5 | 2023 | 13235 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 172 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2015 | 245 | 0.100 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 137 | 0.100 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 45 | 0.090 |
Why?
|
| Foster Home Care | 1 | 2012 | 20 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 640 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 124 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2023 | 251 | 0.090 |
Why?
|
| Losartan | 1 | 2011 | 36 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 63 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2011 | 63 | 0.090 |
Why?
|
| Arthritis | 1 | 2011 | 85 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 115 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2015 | 539 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 525 | 0.090 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 285 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 236 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 426 | 0.080 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 136 | 0.080 |
Why?
|
| Texas | 4 | 2019 | 3664 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1095 | 0.080 |
Why?
|
| Legislation, Drug | 1 | 2009 | 9 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 2750 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2286 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 207 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 410 | 0.080 |
Why?
|
| Financing, Personal | 1 | 2008 | 10 | 0.070 |
Why?
|
| Social Behavior | 1 | 2010 | 230 | 0.070 |
Why?
|
| Canada | 1 | 2009 | 343 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 760 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 23 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 279 | 0.070 |
Why?
|
| Demography | 2 | 1999 | 243 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8627 | 0.060 |
Why?
|
| Life Style | 1 | 2008 | 457 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 45 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 466 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 330 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 327 | 0.060 |
Why?
|
| Parents | 1 | 2012 | 1073 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 239 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2021 | 804 | 0.050 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 4 | 0.050 |
Why?
|
| Nonprescription Drugs | 1 | 2024 | 54 | 0.050 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 10 | 0.050 |
Why?
|
| Drug Overdose | 1 | 2024 | 75 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 61 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 112 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1411 | 0.050 |
Why?
|
| Doxepin | 1 | 2002 | 1 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 874 | 0.050 |
Why?
|
| Pain Management | 1 | 2024 | 202 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 155 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2001 | 10 | 0.040 |
Why?
|
| Cholesterol | 1 | 2023 | 570 | 0.040 |
Why?
|
| Utilization Review | 1 | 2000 | 41 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2000 | 67 | 0.040 |
Why?
|
| Obesity | 1 | 2012 | 2436 | 0.040 |
Why?
|
| Physicians, Family | 1 | 2000 | 38 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 77 | 0.040 |
Why?
|
| Louisiana | 2 | 1996 | 137 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 396 | 0.040 |
Why?
|
| Chlordiazepoxide | 1 | 1999 | 1 | 0.040 |
Why?
|
| Dextropropoxyphene | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pharmacy | 1 | 2019 | 20 | 0.040 |
Why?
|
| Diazepam | 1 | 1999 | 21 | 0.040 |
Why?
|
| Dipyridamole | 1 | 1999 | 22 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 12 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 36189 | 0.040 |
Why?
|
| Health Services Research | 1 | 2000 | 188 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 562 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 66 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 73 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 1998 | 132 | 0.030 |
Why?
|
| Contraindications | 1 | 1997 | 77 | 0.030 |
Why?
|
| Seizures | 1 | 2022 | 889 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 247 | 0.030 |
Why?
|
| Emergencies | 1 | 1998 | 187 | 0.030 |
Why?
|
| Survival Rate | 2 | 2019 | 2204 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 446 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1996 | 35 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 593 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 549 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 53 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 76 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 50 | 0.020 |
Why?
|
| Valsartan | 1 | 2011 | 23 | 0.020 |
Why?
|
| Fosinopril | 1 | 2011 | 3 | 0.020 |
Why?
|
| Lisinopril | 1 | 2011 | 23 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 14 | 0.020 |
Why?
|
| Captopril | 1 | 2011 | 26 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1782 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 27 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 3041 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 715 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 6570 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1997 | 36 | 0.010 |
Why?
|
| Health Services | 1 | 1997 | 73 | 0.010 |
Why?
|